KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Alnylam Pharmaceuticals (ALNY) Receivables - Other: 2018-2021

Alnylam Pharmaceuticals' Receivables - Other was N/A to $500.0 million in Q2 2021 from the same period last year, while for Jun 2021 it was $500.0 million, marking a year-over-year change of. This contributed to the annual value of $500.0 million for FY2020, which is N/A change from last year.
According to the latest figures from Q2 2021, Alnylam Pharmaceuticals' Receivables - Other is $500.0 million, which was down 0.00% from $500.0 million recorded in Q1 2021.
Alnylam Pharmaceuticals' Expense - Property Taxes and Insurance's 5-year high stood at $181 during Q3 2009, with a 5-year trough of $181 in Q3 2009.
Its 2-year average for Receivables - Other is $500.0 million, with a median of $500.0 million in 2021.